NEW YORK, November 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Quarter Results07.11.2024 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Immunic, Inc. Reports Third Quarter 2024 Financial Resultsand Provides Corporate Update– ...

People with celiac disease, lupus, type 1 diabetes, and Sjögren’s syndrome can also be at risk ... Regular follow-up with an endocrinologist is essential to monitor thyroid function and adjust ...